quinta-feira, 8 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 11, 2025

Fed's rate cut takeaways, Eric Jackson's bull case for Nextdoor

View original at finance.yahoo.com
Fed's rate cut takeaways, Eric Jackson's bull case for Nextdoor Morning Brief host Julie Hyman takes on the day's morning market developments on December 11, 2025…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI and Agentic AI specifically can now map onto local commerce opportunity in ways previous attempts couldn't

    80% confidence
  • Angie was a $2 billion business from lead generation a couple years ago, representing open ground for Nextdoor

    80% confidence
  • Job growth has been overstated by 60,000 per month, with actual negative job growth of 20,000 per month

    80% confidence
  • Inflation is higher on my list of concerns than what the FOMC is signaling

    80% confidence
  • AI may be impacting job market on the margins but not a major driving factor

    80% confidence
  • Webvan, Cosmo, and Pets.com were sound ideas just built at the wrong time, now succeeded by Instacart and Chewy

    80% confidence
  • If productivity doesn't prove as accretive to economy, expected productivity gains won't materialize

    80% confidence
  • Fed forecasts one additional interest rate reduction in 2026

    80% confidence
  • Nextdoor is one of the most misunderstood platforms in the market

    80% confidence
  • Nextdoor has 100 million verified real users with no spam or robots

    80% confidence
  • Silent dissents and voting dissents speak to a higher bar for cuts next year regardless of who next Fed chair is

    80% confidence
  • Online prices showing we're still in the midst of increasing prices from goods side going into next year

    80% confidence
  • Insurance cuts are over and Fed is poised to take a pause in the new year

    80% confidence
  • Major inflation driver is tariff inflation on goods side, not services side

    80% confidence
  • Tariff inflation could peak in Q1 2026 unless new tariff announcements are made

    80% confidence
  • GDP forecast raised to 2.3% for 2026

    80% confidence
  • Under Nirav Tolia, notifications were cut by 80% with no effect on 21 million weekly active users

    80% confidence
  • Too early to say AI is boosting productivity, though surprised to see 2% productivity growth

    80% confidence

Data points we hold from this source

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Fed's rate cut takeaways, Eric Jackson's bull case for Nextdoor — Source | Via News | pt.VIA.NEWS